We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

EKF Diagnostics

EKF Diagnostics is a leading global diagnostics and biotechnology company that delivers advanced solutions in point-o... read more Featured Products: More products

Download Mobile App





EKF Presents Cutting-Edge Point-Of-Care Diagnostic Solutions

By LabMedica International staff writers
Posted on 12 Nov 2024

EKF Diagnostics (Cardiff, Wales, UK) is attending MEDICA 2004 where the company is showcasing its diagnostic technologies and biotechnology solutions that empower healthcare and medical providers to make informed clinical decisions through point-of-care (POC) testing and life sciences applications. More...

EKF leads the way with cutting-edge POC diagnostic solutions that empower healthcare professionals and patients with rapid, accurate, and accessible testing capabilities and results. The company’s technologies enable informed decision-making, timely interventions, and improved patient outcomes at the POC. At this year’s MEDICA, EKF is demonstrating its POC medical devices and in-vitro diagnostic (IVD) tests for use at or near the patient’s location, engineered for fast and precise results, allowing healthcare professionals to make swift decisions. This includes EKF’s diabetes POC analyzers that measure glucose, lactate, glycated hemoglobin (HbA1C), and whole blood beta-hydroxybutyrate (BHB). These analyzers offer rapid and reliable results, giving practitioners and patients the critical information needed for clinical or lifestyle decisions within minutes. Among EKF’s diabetes point-of-care analyzers exhibited at MEDICA 2024 are Biosen C-Line, Quo-Test, STAT-Site WB, and Quo-Lab. The new Biosen C-Line, an advanced version of its industry-leading rapid benchtop glucose and lactate analyzer, has been designed to enhance usability with the latest color, touch screen, and advanced connectivity, enabling the device to seamlessly connect with hospital and laboratory IT systems, via EKF Link, to ensure patient results are quickly and securely available to clinicians.

EKF’s hemoglobin POC analyzers exhibited at MEDICA 2024 offer quick and convenient on-site blood testing, minimizing result turnaround times and enhancing patient diagnosis and outcomes. These include the DiaSpect Tm hand-held hemoglobin analyzer and Hemo Control POC hemoglobin analyzer that provides quantitative, lab-quality hemoglobin results after 25 seconds. Both devices are powered by EKF Link, which is an optional software platform that provides a flexible and secure method for connecting POC devices to hospital and laboratory IT systems. EKF Link is a middleware solution that helps healthcare providers manage their POC analyzers and associated data on one platform. A flexible and open solution that can be interfaced with most POC analyzers, allowing real-time data management, including patient test results, QC results, operator management, and analyzer configuration.

Related Links:
EKF Diagnostics


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The AidaBREAST assay integrates multimodal data to provide patient-specific 10-year recurrence risk and individualized predictions of radiation therapy benefit (photo courtesy of PreludeDx)

Validated Test Predicts Recurrence Risk and Radiation Benefit in Early-Stage Breast Cancer

For women with early-stage invasive breast cancer who undergo breast-conserving surgery, clinicians must assess both the risk of locoregional recurrence and the potential benefit of adjuvant radiation therapy.... Read more

Microbiology

view channel
Image: Invasive aspergillosis (IA) is a potentially life-threatening infection caused by Aspergillus mold that primarily affects people with severely weakened immune systems. (Image Credit: Adobe Stock)

Rapid Urine Test Aids Diagnosis of Invasive Aspergillosis

Invasive aspergillosis is an uncommon mold infection in the general population but can pose serious risks for people with weakened immune defenses. Diagnosis can be difficult because existing approaches... Read more

Technology

view channel
Image: The laser-based photoacoustic spectroscopy setup consists of a Mid-IR laser equipped with three QCL modules covering wavelengths from 5.6 μm to 12.9 μm, two silver coated mirrors (SCM), a dichroic mirror (DM) with a transmittance of 90%, a thermal power sensor head (PM) to monitor the output laser power, a mechanical chopper (MC) for frequency modulation and a CEPAS-detector with a self-designed swab holder (SH). (Credit: Graunke, T., Scholz, T., Pieniak, M. et al. Scientific Reports (2026). https://doi.org/10.1038/s41598-026-68298-9)

Laser-Based Swab Analysis Shows Promise for Detecting Disease-Linked Odor Patterns

Disease-related changes in volatile organic compounds can alter body odor, producing measurable patterns in exhaled breath and bodily fluids. Current analytical methods can be complex, time-consuming,... Read more

Industry

view channel
Image: Natera\'s MCED assay analyzes cell-free DNA in blood to screen for multiple cancers (Image Credit: Adobe Stock)

Multi-Cancer Screening Blood Test Gains FDA Breakthrough Designation

Natera Inc.’s (Austin, TX, USA) multi-cancer early detection (MCED) assay has received Breakthrough Device designation (BDD) from the U.S. Food and Drug Administration (FDA). The assay analyzes cell-free... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.